SPECIAL NOTICE
A -- Risk factors and sequelae of MIS-C & COVID-19 VE - Modified Work
- Notice Date
- 2/10/2022 11:44:51 AM
- Notice Type
- Justification
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- CDC OFFICE OF ACQUISITION SERVICES ATLANTA GA 30333 USA
- ZIP Code
- 30333
- Solicitation Number
- 10297
- Archive Date
- 03/12/2022
- Point of Contact
- Mark Draluck, Phone: 7704880938, Pellumbeshe Hoxhaj
- E-Mail Address
-
syq1@cdc.gov, kfx2@cdc.gov
(syq1@cdc.gov, kfx2@cdc.gov)
- Award Number
- 75D30121C10297
- Award Date
- 02/04/2022
- Description
- CDC awarded modification number 00001 to contract number 75D30121C10297 to The Children�s Hospital Corporation, 300 Longwood Ave, Boston, MA, 02115-5724, on 4 February 2022, in the amount of $994,000.00. This notice makes available a Justification and Approval for Other than Full and Open Competition (J&A) that applies to this contract. This contract modification was issued under the authority of FAR 6.302-2, Unusual and Compelling Urgency, in accordance with the CDC Class Justification for Other than Full and Open Competition � COVID 19 Response.� As the COVID-19 pandemic has progressed, CDC requires a better understanding of the clinical manifestations and risk factors associated with COVID-19 illness and MIS-C, particularly among children who are hospitalized. CDC also urgently needs to understand vaccine effectiveness (VE) of newly licensed vaccines against COVID-19 as these vaccines roll out, including against emerging variants, among hospitalized children. The services require the Contractor to: (1) build upon the Network to study COVID-19 and MIS-C in hospitalized children; (2) continue enrollment of patients into the study across multiple United States sites; (3) update and populate the database of study data to incorporate the identified study objectives; (4) continue contributing to the biospecimen repository to facilitate analyses evaluating mechanisms of susceptibility to severe respiratory virus infection; (5) describe the spectrum of clinical manifestations and exposure history of COVID-19 and MIS-C patients; and (6) identify risk factors for severe COVID-19 and MIS-C outcomes. The services also require the Contractor to conduct research into four study objectives: (1) Risk Factor Study. (2) Rheumatologic/Immunologic Study.� (3) Neurologic /Neurocognitive sequelae Study. And (4) Vaccine Effectiveness (VE) Evaluation. Purpose of the Modification: It is this 4th Vaccine Effectiveness objective that is currently of critical importance.� No other CDC network has the potential to provide data on vaccine effectiveness in the most recent and youngest authorized group of children, those aged 5-11, that will be considered and incorporated in the upcoming vaccine policy discussions.� The primary focus of this contract modification will be to support enrollment of case and control patients for COVID-19 effectiveness evaluations by increasing the number of cases and controls by up to an additional 1,000 each. In accordance with the attached J&A, The Children�s Hospital Corporation was determined to be the only responsible source capable of providing this modified work under this contract within the required time period. The attached J&A is being made available within 30 days of contract award in accordance with FAR 6.305(b) and will remain active for 30 days in accordance with FAR 6.305(d)(3).
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/49b9fc9f584247efa2823809aee62a59/view)
- Place of Performance
- Address: Boston, MA 02115, USA
- Zip Code: 02115
- Country: USA
- Zip Code: 02115
- Record
- SN06238747-F 20220212/220210230106 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |